Chronic Myeloid Leukemia, Chronic Phase Clinical Trial
Official title:
Cytochrome P450 Inhibition With Ketoconazole to Decrease Dosage and Costs of Dasatinib for Chronic Myelogenous Leukemia
This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome inhibition with ketoconazole to reduce dasatinib dosage for adults with chronic myelogenous leukemia. Researchers will describe response rates and adverse events.
Dasatinib is a second-generation tyrosine kinase inhibitor that is metabolized by the cytochrome P450. Dasatinib has shown efficacy in patients with chronic myelogenous leukemia. Standard-dose dasatinib is 50mg-140mg/day orally, continuously. However, when combined with a strong CYP3A4 inhibitor, a dose reduction of 75% is warranted. This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome inhibition with ketoconazole to reduce the dosage and costs of dasatinib for adults with chronic myelogenous leukemia. Researchers will describe cytogenetic and molecular response rates at 3, 6, and 12 months and adverse events (i.e., pleural effusion) associated with this strategy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
| Terminated |
NCT04006847 -
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06368414 -
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT04126681 -
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
|
Phase 2 | |
| Not yet recruiting |
NCT05543161 -
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
|
||
| Recruiting |
NCT03610971 -
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
|
Phase 2 | |
| Completed |
NCT03332511 -
Efficacy and Safety of Nilotinib in CML-CP
|
Phase 4 | |
| Active, not recruiting |
NCT06233890 -
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
|
||
| Completed |
NCT03882281 -
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT03459534 -
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
|
Phase 3 | |
| Completed |
NCT03885830 -
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
|
||
| Active, not recruiting |
NCT04147533 -
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT03942094 -
Nilotinib for First-line Newly Diagnosed CML-CP Patients
|
Phase 3 | |
| Active, not recruiting |
NCT03933852 -
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
|
||
| Recruiting |
NCT05311943 -
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
|
Phase 3 | |
| Active, not recruiting |
NCT04160546 -
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
|
Phase 2 | |
| Recruiting |
NCT04677439 -
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
|
Phase 4 | |
| Active, not recruiting |
NCT03722420 -
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
|
Phase 3 | |
| Not yet recruiting |
NCT06163430 -
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT02977312 -
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
|
N/A |